Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SHBG | P04278 | 1/20 | 0.61 |
| ▸ | MDH1 | P40925 | 2/20 | 0.53 |
| ▸ | MDH2 | P40926 | 2/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | KIF11 | P52732 | 3/20 | 0.39 |
| ▸ | IDO1 | P14902 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.39 |
| ▸ | CES2 | O00748 | 1/20 | 0.38 |
| ▸ | CES1 | P23141 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26764530 | 0.81 | SHBG (0.61) | SHBGMDH1MDH2CYP3A4SMN1; SMN2 | |
| SCHEMBL10515698 | 0.80 | SHBG (0.67) | SHBGMDH1MDH2CYP3A4SMN1; SMN2 | |
| SCHEMBL15294399 | 0.78 | NPC1 (0.48) | SMN1; SMN2TAAR1ALDH1A1TSHRKIF11 | |
| SCHEMBL8768818 | 0.78 | SHBG (0.64) | SHBGMDH1MDH2CYP3A4SMN1; SMN2 | |
| SCHEMBL12901182 | 0.76 | SHBG (0.61) | SHBGMDH1MDH2CYP3A4SMN1; SMN2 | |
| SCHEMBL793347 | 0.76 | TAAR1 (0.60) | TAAR1ALDH1A1TSHRKIF11IDO1 | |
| SCHEMBL9081437 | 0.76 | SHBG (0.61) | SHBGMDH1MDH2CYP3A4SMN1; SMN2 | |
| SCHEMBL2037077 | 0.76 | SHBG (0.61) | SHBGMDH1MDH2CYP3A4SMN1; SMN2 | |
| SCHEMBL21138351 | 0.76 | SHBG (0.68) | SHBGMDH1MDH2CYP3A4SMN1; SMN2 | |
| SCHEMBL8798776 | 0.76 | SHBG (0.61) | SHBGMDH1MDH2CYP3A4SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230365617-A1 | SAPONIN DERIVATIVES FOR USE IN MEDICINE | SAPREME TECHNOLOGIES B.V. (NL) | 2023-11-16 | — | — | US | disclosed |
| EP-2128136-A1 | 2-PHENYLNICOTINIC ACID DERIVATIVE | Nippon Zoki Pharmaceutical Co., Ltd. (JP) | 2009-12-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230365617-A1 | SAPONIN DERIVATIVES FOR USE IN MEDICINE | HAVCR2, TTR, PYGL | SHBG 168/4885MDH1 2815/4885MDH2 3518/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.